clofibrate has been researched along with Hypertension in 51 studies
angiokapsul: contains clofibrate & insoitolnicotinate
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The present study examined whether long-term induction of renal fatty acid omega-hydroxylase with clofibrate would alter the development of hypertension in Dahl SS/Jr rats." | 7.68 | Clofibrate prevents the development of hypertension in Dahl salt-sensitive rats. ( Frohlich, B; Ma, YH; Markham, B; Roman, RJ, 1993) |
| "Clofibrate prevented the increase in SBP produced by salt administration, reduced the sodium balance, and further reduced plasma and tissue thyroid hormone levels." | 5.37 | Effects of clofibrate on salt loading-induced hypertension in rats. ( Cruz, A; Moreno, JM; Osuna, A; Pérez-Abud, R; Quesada, A; Rodríguez-Gómez, I; Vargas, MÁ; Wangensteen, R, 2011) |
| " Therefore, our aim was to study whether clofibrate-induced peroxisome proliferator-activated receptor-alpha (PPAR-α) stimulation is able to prevent alterations in cardiac functioning derived from RAS overstimulation in the left ventricle of rats with hypertension secondary to aortic coarctation and to improve antioxidant defenses." | 3.83 | Peroxisome proliferator-activated receptor-α stimulation by clofibrate favors an antioxidant and vasodilator environment in a stressed left ventricle. ( Cervantes-Pérez, LG; Del Valle-Mondragón, L; Ibarra-Lara, L; Oidor-Chan, VH; Pastelín-Hernández, GS; Pérez-Severiano, F; Ramírez-Ortega, M; Sánchez-Aguilar, M; Sánchez-Mendoza, A; Soria-Castro, E; Torres-Narváez, JC; Zarco-Olvera, G, 2016) |
| " Clofibrate treatment reduced SBP by 26%±2% and proteinuria by 43%±9% in SHR but not in WKY rats." | 3.80 | PPARα ligand clofibrate ameliorates blood pressure and vascular reactivity in spontaneously hypertensive rats. ( Newaz, M; Yousefipour, Z, 2014) |
| "Inducing renal cytochrome P4504A (P4504A) activity with clofibrate prevents the development of hypertension in Dahl salt-sensitive (Dahl S) rats." | 3.70 | Effects of lipid-lowering agents in the Dahl salt-sensitive rat. ( Alonso-Galicia, M; Roman, RJ; Wilson, TW, 1998) |
| "Clofibrate has been reported to prevent the development of hypertension in Dahl S rats, but its mechanism of action remains to be determined." | 3.70 | Induction of P4504A activity improves pressure-natriuresis in Dahl S rats. ( Alonso-Galicia, M; Frohlich, B; Roman, RJ, 1998) |
| " The present study examined whether long-term induction of renal fatty acid omega-hydroxylase with clofibrate would alter the development of hypertension in Dahl SS/Jr rats." | 3.68 | Clofibrate prevents the development of hypertension in Dahl salt-sensitive rats. ( Frohlich, B; Ma, YH; Markham, B; Roman, RJ, 1993) |
| "Results of recent clinical trials on secondary prevention of ischemic heart disease indicate that judicious, long-term administration of adrenergic beta blockers and platelet-active drugs such as aspirin and Persantine (dipyridamole) would seem to yield protection against mortality associated with acute myocardial infarction, including sudden death." | 3.67 | Clinical trials on the efficacy of pharmacologic intervention reducing mortality from cardiovascular diseases. ( Borhani, NO, 1985) |
| " It is suggested that the liver lesions of this woman may be related to long-term administration of hypolipidemic drug clofibrate for hypercholesteremia and the lesions could be one of the precursor changes of human hepatocellular carcinoma." | 3.66 | Adenoma with multiple hyperplastic nodules in noncirrhotic liver possibly related to long-term administration of a hypolipidemic drug. ( Mori, H; Sugie, S; Takahashi, M; Tanaka, T, 1982) |
| "Metabolic syndrome is associated with increased cardiovascular risk." | 2.41 | [Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome]. ( Idzior-Waluś, B, 2001) |
| "Clofibrate prevented the increase in SBP produced by salt administration, reduced the sodium balance, and further reduced plasma and tissue thyroid hormone levels." | 1.37 | Effects of clofibrate on salt loading-induced hypertension in rats. ( Cruz, A; Moreno, JM; Osuna, A; Pérez-Abud, R; Quesada, A; Rodríguez-Gómez, I; Vargas, MÁ; Wangensteen, R, 2011) |
| "Type V hyperlipemia is not very common." | 1.26 | [Type V hyperlipemia. 54 cases (author's transl)]. ( Beaumont, V; Buxtorf, JC; Jacotot, B; Schlesinger, M, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 34 (66.67) | 18.7374 |
| 1990's | 3 (5.88) | 18.2507 |
| 2000's | 8 (15.69) | 29.6817 |
| 2010's | 6 (11.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Willson, TM | 1 |
| Brown, PJ | 1 |
| Sternbach, DD | 1 |
| Henke, BR | 1 |
| Yousefipour, Z | 1 |
| Newaz, M | 2 |
| Ibarra-Lara, L | 2 |
| Del Valle-Mondragón, L | 2 |
| Soria-Castro, E | 2 |
| Torres-Narváez, JC | 1 |
| Pérez-Severiano, F | 3 |
| Sánchez-Aguilar, M | 2 |
| Ramírez-Ortega, M | 1 |
| Cervantes-Pérez, LG | 3 |
| Pastelín-Hernández, GS | 2 |
| Oidor-Chan, VH | 1 |
| Zarco-Olvera, G | 1 |
| Sánchez-Mendoza, A | 2 |
| Zhou, Y | 2 |
| Luo, P | 1 |
| Chang, HH | 2 |
| Huang, H | 2 |
| Yang, T | 1 |
| Dong, Z | 1 |
| Wang, CY | 2 |
| Wang, MH | 3 |
| Ying, CJ | 1 |
| Noguchi, T | 1 |
| Aso, H | 1 |
| Ikeda, K | 1 |
| Yamori, Y | 1 |
| Nara, Y | 1 |
| Del Valle, L | 1 |
| Rubio-Ruíz, E | 1 |
| Martínez-Lazcano, JC | 1 |
| Gelosa, P | 1 |
| Banfi, C | 1 |
| Gianella, A | 1 |
| Brioschi, M | 1 |
| Pignieri, A | 1 |
| Nobili, E | 1 |
| Castiglioni, L | 1 |
| Cimino, M | 1 |
| Tremoli, E | 1 |
| Sironi, L | 1 |
| Cruz, A | 1 |
| Rodríguez-Gómez, I | 1 |
| Pérez-Abud, R | 1 |
| Vargas, MÁ | 1 |
| Wangensteen, R | 1 |
| Quesada, A | 1 |
| Osuna, A | 1 |
| Moreno, JM | 1 |
| Ibarra-Lara, Mde L | 1 |
| Escalante, B | 1 |
| Vargas-Robles, H | 1 |
| Pastelín, G | 1 |
| Sánchez-Mendoza, MA | 1 |
| Williams, JM | 1 |
| Zhao, X | 1 |
| Imig, JD | 1 |
| Pollock, DM | 1 |
| Blanton, A | 1 |
| Fidelis, P | 1 |
| Oyekan, A | 1 |
| Du, J | 1 |
| Wu, JF | 1 |
| Sankaralingam, S | 1 |
| Desai, KM | 1 |
| Wilson, TW | 2 |
| Oliver, MF | 5 |
| Marshall, AJ | 1 |
| Mori, H | 1 |
| Tanaka, T | 1 |
| Sugie, S | 1 |
| Takahashi, M | 1 |
| Bock, KD | 1 |
| Rose, G | 1 |
| Akhmeteli, MA | 1 |
| Kazakov, IuM | 1 |
| Chaialo, PP | 1 |
| Tokar', AV | 1 |
| Rudaia, ES | 1 |
| Roman, RJ | 3 |
| Ma, YH | 1 |
| Frohlich, B | 2 |
| Markham, B | 1 |
| Alonso-Galicia, M | 2 |
| Idzior-Waluś, B | 1 |
| Mono, G | 1 |
| Kuhn, E | 1 |
| Schlesinger, M | 1 |
| Jacotot, B | 1 |
| Beaumont, V | 1 |
| Buxtorf, JC | 1 |
| Basta, LL | 1 |
| Williams, C | 1 |
| Kioschos, JM | 1 |
| Spector, AA | 1 |
| Rumpf, KW | 1 |
| Quellhrost, E | 1 |
| Scheler, F | 1 |
| Parsons, WB | 1 |
| Santrůcek, M | 1 |
| Geizerová, H | 1 |
| Hejl, Z | 1 |
| Grafnetter, D | 1 |
| Green, KG | 1 |
| Heady, A | 1 |
| Borhani, NO | 1 |
| Miettinen, TA | 2 |
| Huttunen, JK | 1 |
| Naukkarinen, V | 1 |
| Strandberg, T | 1 |
| Vanhanen, H | 1 |
| Murata, Y | 1 |
| Tani, M | 1 |
| Amano, M | 1 |
| Menotti, A | 1 |
| Puddu, V | 1 |
| Porcellati, G | 1 |
| Valcavi, U | 1 |
| Gaiti, A | 1 |
| Albeaux-Fernet, M | 1 |
| Gelinet, M | 1 |
| Deribreux, J | 1 |
| Saheta, NP | 1 |
| Neugebauer, A | 1 |
| Trenckmann, H | 1 |
| Duck, HJ | 1 |
| Fleischmann, HJ | 1 |
| Schauer, J | 1 |
| Begg, TB | 1 |
| Likoff, W | 1 |
| Takayasu, K | 1 |
| Tada, T | 1 |
| Okada, F | 1 |
| Yoshikawa, I | 1 |
| Nakano, M | 1 |
| Nakamura, Y | 1 |
| Fejfar, Z | 1 |
| Vanĕcek, R | 1 |
| Harrold, BP | 1 |
8 reviews available for clofibrate and Hypertension
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligand | 2000 |
Strategy of reducing coronary risk and the use of drugs.
Topics: Adrenergic beta-Antagonists; Cardiovascular Agents; Cerebrovascular Disorders; Cholesterol; Clofibra | 1984 |
Drug therapy of hypertension and ischaemic heart disease.
Topics: Adrenergic beta-Antagonists; Adult; Angina Pectoris; Antihypertensive Agents; Aspirin; Clofibrate; C | 1981 |
[Prevention of cardiovascular diseases].
Topics: Adult; Arteriosclerosis; Blood Pressure; Cholesterol; Clofibrate; Coronary Disease; Humans; Hyperten | 1982 |
[Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome].
Topics: Cardiovascular Diseases; Clofibrate; Fenofibrate; Hemostasis; Humans; Hyperinsulinism; Hyperlipidemi | 2001 |
[Cardiotoxic effects of drugs and various other substances. A review].
Topics: Adrenergic Agonists; Amphetamine; Antimony; Arrhythmias, Cardiac; Arsenic Poisoning; Catecholamines; | 1978 |
Iatrogenic cardiovascular disease (an aspect of preventive cardiology).
Topics: Abnormalities, Drug-Induced; Analgesics; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Antidepressi | 1968 |
[Drug prevention of coronary disease].
Topics: Anticholesteremic Agents; Antihypertensive Agents; Cholestyramine Resin; Clofibrate; Coronary Diseas | 1972 |
5 trials available for clofibrate and Hypertension
| Article | Year |
|---|---|
Cholesterol, coronaries, clofibrate and death.
Topics: Adult; Cholesterol; Clinical Trials as Topic; Clofibrate; Coronary Disease; Death, Sudden; Humans; H | 1978 |
Long-term use of probucol in the multifactorial primary prevention of vascular disease.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Cerebrovascular Disorders; Cholesterol, HDL; C | 1986 |
Prevention of coronary heart disease--propaganda, promises, problems, and prospects.
Topics: Adult; Arteriosclerosis; Cholesterol; Clinical Trials as Topic; Clofibrate; Coronary Disease; Diet; | 1986 |
Strategy, yield and risks of controlling plasma lipids in the primary prevention of coronary heart disease.
Topics: Adult; Arteriosclerosis; Cholesterol; Clinical Trials as Topic; Clofibrate; Coronary Disease; Diet; | 1985 |
General therapeutic and prophylactic problems in the treatment of atherosclerosis.
Topics: Aged; Arteriosclerosis; Clinical Trials as Topic; Clofibrate; Coronary Disease; Diet Therapy; Dietar | 1972 |
38 other studies available for clofibrate and Hypertension
| Article | Year |
|---|---|
PPARα ligand clofibrate ameliorates blood pressure and vascular reactivity in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Aorta; Biomarkers; Blood Pressure; Clofibrate; Disease Models, Ani | 2014 |
Peroxisome proliferator-activated receptor-α stimulation by clofibrate favors an antioxidant and vasodilator environment in a stressed left ventricle.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Antioxidants; Aortic Coarct | 2016 |
Colfibrate attenuates blood pressure and sodium retention in DOCA-salt hypertension.
Topics: Animals; Blood Pressure; Clofibrate; Cytochrome P-450 CYP4A; Desoxycorticosterone; Hydroxyeicosatetr | 2008 |
The role of cytochrome p-450 in salt-sensitive stroke in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Anticholesteremic Agents; Arterioles; Aryl Hydrocarbon Hydroxylases; Blood Pressure; Cerebr | 2008 |
PPARalpha stimulation exerts a blood pressure lowering effect through different mechanisms in a time-dependent manner.
Topics: Angiotensin II; Animals; Antioxidants; Aortic Coarctation; Blood Pressure; Clofibrate; Gene Expressi | 2010 |
Peroxisome proliferator-activated receptor {alpha} agonism prevents renal damage and the oxidative stress and inflammatory processes affecting the brains of stroke-prone rats.
Topics: Animals; Blotting, Western; Brain; Chemokine CCL2; Clofibrate; Disease Models, Animal; Fenofibrate; | 2010 |
Effects of clofibrate on salt loading-induced hypertension in rats.
Topics: Animals; Anticholesteremic Agents; Blood Pressure; Clofibrate; Heart Rate; Hypertension; Male; Rats; | 2011 |
Endothelial nitric oxide synthase impairment is restored by clofibrate treatment in an animal model of hypertension.
Topics: Animals; Biopterins; Clofibrate; Disease Models, Animal; GTP Cyclohydrolase; Hypertension; Hypolipid | 2012 |
Peroxisome proliferator-activated receptor-alpha activation reduces salt-dependent hypertension during chronic endothelin B receptor blockade.
Topics: Animals; Blood Pressure; Clofibrate; Cytochrome P-450 CYP4A; Dose-Response Relationship, Drug; Drug | 2005 |
NAD(P)H oxidase/nitric oxide interactions in peroxisome proliferator activated receptor (PPAR)alpha-mediated cardiovascular effects.
Topics: Animals; Blood Pressure; Clofibrate; Desoxycorticosterone; Endothelin-1; Free Radicals; Hypertension | 2005 |
Induction of renal 20-hydroxyeicosatetraenoic acid by clofibrate attenuates high-fat diet-induced hypertension in rats.
Topics: Animals; Blood Pressure; Clofibrate; Cytochrome P-450 CYP4A; Dietary Fats; Enzyme Induction; Hydroxy | 2006 |
Chronic clofibrate administration prevents saline-induced endothelial dysfunction and oxidative stress in young Sprague-Dawley rats.
Topics: Animals; Anions; Anticholesteremic Agents; Carbonates; Carotid Arteries; Clofibrate; Endothelium; Hy | 2008 |
Adenoma with multiple hyperplastic nodules in noncirrhotic liver possibly related to long-term administration of a hypolipidemic drug.
Topics: Aged; Carcinoma, Hepatocellular; Clofibrate; Female; Humans; Hypercholesterolemia; Hyperplasia; Hype | 1982 |
[Benefit-risk evaluation in the physician's therapy decisions].
Topics: Clofibrate; Decision Making; Hypertension; Patient Care Planning; Risk | 1980 |
Strategy of prevention: lessons from cardiovascular disease.
Topics: Adult; Aged; Cholesterol; Cholesterol, Dietary; Clofibrate; Contraceptives, Oral; Coronary Disease; | 1981 |
[Blood viscosity and hematocrit indices in arteriosclerosis].
Topics: Adolescent; Adult; Arteriosclerosis; Blood Viscosity; Clofibrate; Coronary Disease; Hematocrit; Huma | 1981 |
[Comparative evaluation of the hypolipidemic effect of cetamiphen, polysponin and miscleron in middle-aged and elderly patients with hypertension].
Topics: Aged; Clofibrate; Drug Combinations; Humans; Hypertension; Hypolipidemic Agents; Middle Aged; Phenyl | 1980 |
Clofibrate prevents the development of hypertension in Dahl salt-sensitive rats.
Topics: Animals; Arachidonic Acid; Blood Pressure; Clofibrate; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzy | 1993 |
Effects of lipid-lowering agents in the Dahl salt-sensitive rat.
Topics: Animals; Blood Pressure; Cholesterol; Clofibrate; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme Sy | 1998 |
Induction of P4504A activity improves pressure-natriuresis in Dahl S rats.
Topics: Animals; Blood Pressure; Clofibrate; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme System; Diet, S | 1998 |
[Type V hyperlipemia. 54 cases (author's transl)].
Topics: Adolescent; Adult; Aged; Alcoholism; Blood Protein Electrophoresis; Child; Child, Preschool; Cholest | 1979 |
Regression of atherosclerotic stenosing lesions of the renal arteries and spontaneous cure of systemic hypertension through control of hyperlipidemia.
Topics: Arteriosclerosis; Cholesterol; Cholestyramine Resin; Clofibrate; Female; Humans; Hyperlipidemias; Hy | 1976 |
[Diabetic nephropathy, hypothyroidism and colfibrate-induced myopathy (author's transl)].
Topics: Adult; Clofibrate; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Diabet | 1976 |
Hyperlipidemia: to treat or not to treat.
Topics: Cerebrovascular Disorders; Cholestyramine Resin; Clofibrate; Coronary Disease; Female; Humans; Hyper | 1975 |
[Experiences of 15 years in the screening of ischaemic heart diseases and arterial hypertension].
Topics: Cholesterol; Clofibrate; Coronary Disease; Czechoslovakia; Humans; Hypertension; Male; Middle Aged; | 1975 |
Blood pressure, cigarette smoking and heart attack in the WHO co-operative trial of clofibrate.
Topics: Bezafibrate; Clofibrate; Coronary Disease; Fibrinogen; Humans; Hypertension; Male; Smoking; World He | 1989 |
Clinical trials on the efficacy of pharmacologic intervention reducing mortality from cardiovascular diseases.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Clofibrate; | 1985 |
Erythema multiforme due to clofibrate.
Topics: Aged; Clofibrate; Erythema Multiforme; Female; Humans; Hyperlipidemias; Hypertension | 1988 |
[Short-term pilot study of the feasibility of multifactor reduction of coronary risk].
Topics: Adult; Arteriosclerosis; Clofibrate; Clopamide; Coronary Disease; Diet Therapy; Dietary Fats; Ergolo | 1973 |
When a drug is the culprit.
Topics: Adult; Aged; Angina Pectoris; Arrhythmias, Cardiac; Clofibrate; Depression; Drug-Related Side Effect | 1973 |
[Biochemical changes in atherosclerosis: current concepts and experimental applications].
Topics: Animals; Arteriosclerosis; Blood Coagulation Disorders; Blood Vessels; Butyrates; Cholesterol; Clofi | 1971 |
[Sheehan's disease followed by severe arterial hypertension with right renal artery stenosis. Discussion of the role of hypopituitarism in atherogenesis].
Topics: Adrenal Cortex Hormones; Adult; Androgens; Arteriosclerosis; Clofibrate; Coronary Disease; Female; H | 1973 |
[Diagnosis and treatment of risk factors in chronic ischemic heart disease].
Topics: Adult; Age Factors; Arteriosclerosis; Cholestyramine Resin; Chronic Disease; Clofibrate; Coronary Di | 1974 |
Symposium on arteriosclerotic heart disease. Medical management of angina pectoris.
Topics: Acute Disease; Angina Pectoris; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Clofibrate; Die | 1972 |
Human plasma fatty acid composition: the features of hyperlipoproteinemia and the influence of -linolenate and clofibrate.
Topics: Adult; Aged; Blood Protein Disorders; Cholesterol; Clofibrate; Diabetes Mellitus; Fatty Acids; Fatty | 1971 |
[Hyperlipiemia and its therapy by clofibrate].
Topics: Administration, Oral; Adult; Aged; Cholesterol; Clofibrate; Fatty Acids, Nonesterified; Female; Huma | 1969 |
Prevention of ischaemic heart disease. Possibilities and problems.
Topics: Adult; Age Factors; Aged; Cholesterol; Clofibrate; Coronary Disease; Czechoslovakia; Diet; Female; H | 1970 |
Diabetic retinopathy and hypertension.
Topics: Adult; Aged; Arteriosclerosis; Blood Pressure; Clofibrate; Diabetic Retinopathy; Exudates and Transu | 1971 |